Cosmo Bio Co Ltd

Capital Structure and Liquidity Cosmo Bio maintains a strong liquidity position with a current ratio of 5.23, indicating a robust ability to meet short-term obligations. The company holds JPY 2.75 billion in cash and equivalents, which is a significant portion of its total assets of JPY 12.66 billion. The debt-to-equity ratio is effectively zero, as the company has no long-term debt, and total liabilities amount to JPY 3.29 billion compared to total equity of JPY 9.37 billion. ### Profitability and Returns The company's profitability is modest, with a net income of JPY 337 million and an operating income of JPY 290 million. The return on equity (ROE) is 3.6%, and the return on assets (ROA) is 2.66%. These figures are below the typical thresholds for high-performing pharmaceutical companies, suggesting that Cosmo Bio's returns are relatively low compared to industry standards. ### Segments and Geographic Exposure Cosmo Bio's business is primarily focused on the domestic Japanese market, with a significant portion of its revenue derived from the sale of research reagents and equipment. The company imports most of its research reagents from the United States and Europe, indicating a reliance on international suppliers. However, the majority of its sales are within Japan, which may expose the company to domestic economic conditions and regulatory changes. ### Growth Trajectory The company's growth trajectory is not explicitly detailed in the provided data, but the current financial snapshot suggests a stable, albeit modest, performance. The operating cash flow is JPY 595 million, while the free cash flow is negative at JPY -128 million, indicating that capital expenditures are outpacing cash generation. The capital expenditure of JPY -281 million suggests ongoing investment in the business, which could be a sign of future growth. ### Risk Factors The risk assessment indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The company's low debt levels and strong cash reserves contribute to its favorable liquidity position. However, the modest profitability and low returns may pose challenges in sustaining growth and competing with higher-margin pharmaceutical companies. ### Recent Events There are no specific recent events or filings mentioned in the provided data that would significantly impact the company's operations or financial position. The company's financial performance appears to be consistent with its historical trends, as reflected in the analyst estimates for EPS and revenue.